Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
NewAmsterdam Pharma reported revenue of $23M in the fiscal year ended Dec 2025, down 50.6% from the year before. Operating income was −$226M, an operating margin of −1002.9%, and net income was −$204M. Operating cash flow of −$148M less capital expenditure of $246,000 left free cash flow of −$148M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | – | 103 | 14.1 | 45.6 | 22.5 |
| Research & development | 29.0 | 86.7 | 159 | 151 | 142 |
| Selling, general & admin | 6.0 | 19.5 | 37.6 | 70.4 | 106 |
| Operating income | −35.0 | −3.6 | −183 | −176 | −226 |
| Interest expense | 0.4 | 0.3 | – | – | – |
| Pre-tax income | −41.8 | −22.6 | −177 | −242 | −204 |
| Income tax | – | – | 0.0 | −0.0 | – |
| Net income | −41.8 | −22.6 | −177 | −242 | −204 |
| Diluted EPS | −3.81 | −1.19 | −2.15 | −2.56 | −1.72 |
| Diluted shares | 11.0 | 19.0 | 82.2 | 94.4 | 118 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | – | – | 340 | 772 | 490 |
| Current assets | – | 478 | 347 | 863 | 676 |
| Net PP&E | – | 0.0 | 0.0 | 0.2 | 0.4 |
| Total assets | – | 478 | 347 | 865 | 769 |
| Payables | – | 11.9 | 16.9 | 4.7 | 9.0 |
| Deferred revenue | – | 13.9 | 8.9 | 6.0 | 4.0 |
| Current liabilities | – | 36.1 | 49.9 | 107 | 85.8 |
| Total liabilities | – | 48.4 | 58.7 | 107 | 85.9 |
| Shareholders' equity | −114 | 430 | 288 | 758 | 683 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −29.5 | 10.7 | −141 | −159 | −148 |
| Capital expenditure | 0.0 | 0.2 | 0.0 | 0.7 | 0.2 |
| Free cash flow | −29.5 | 10.4 | −141 | −159 | −148 |
| Depreciation & amortisation | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 |
| Stock-based compensation | 1.2 | 4.1 | 24.6 | 33.6 | 59.4 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | – | −86.3% | 223.4% | −50.6% |
| Operating margin | – | −3.5% | −1298.6% | −386.9% | −1002.9% |
| Net margin | – | −22.0% | −1255.8% | −530.3% | −905.7% |
| Return on equityBlank when equity is negative | – | −5.3% | −61.4% | −31.9% | −29.8% |
| ROCEEBIT ÷ (assets − current liabilities) | – | −0.8% | −61.6% | −23.3% | −33.0% |
| Free cash flow margin | – | 10.2% | −1002.4% | −349.5% | −657.8% |
| Cash conversion (CFO ÷ net income) | 0.71x | −0.47x | 0.80x | 0.66x | 0.73x |
| Interest cover | −85.1x | −12.4x | – | – | – |
| Current ratio | – | 13.3x | 6.95x | 8.08x | 7.88x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.